1.A Clinical Trial of Polybutine Syrup to Pediatric G-I Symptomes.
Il Sin MOON ; Kyung Sik RO ; Ik Jun LEE ; Du Bong LEE
Journal of the Korean Pediatric Society 1982;25(1):41-44
This clinical trial was undertaken on 32 infants and chhildren who had G-I symptoms caused by a few diseases, such as meningitis, parenteral infection and intestinal infection. Out of 32 patients, six had vomiting only, caused by meingitis and habitual vomiting, eighteen had vomiting and diarrhea both which caused by parenteral infection and rest of them (8) had diarrhea only, caused by intestinal infection. Polybutine syrup, which 5.0 ml contain 24 mg of trimebutine, was given to these patients as follows; 2.5 ml twice a day at 6 months of age, 5.0 ml twice a day at 6 months to one year and 10 ml three times a day at 1-5 years of age. In ten of 24 patients, who had vomiting only (6), vomiting and diarrhea (18), the symptoms were improved within 48 hours, and rest of them (10) was also shown the improvement of their symptoms within 5 days after medication. In comparison of polybutine treated group and not treated group, the effectiveness of polybutine treatment for the symptoms was statistically meaningful.
Diarrhea
;
Humans
;
Infant
;
Meningitis
;
Trimebutine
;
Vomiting
2.The Effect of Trimebutine and/or Helicobacter pylori Eradication on the Gastroesophageal Reflux Disease, Irritable Bowel Syndrome, and Functional Dyspepsia Overlapping Disorders
Jannis KOUNTOURAS ; Emmanouel GAVALAS ; Michael DOULBERIS ; Stergios A POLYZOS ; Apostolis PAPAEFTHYMIOU ; Maria TOULOUMTZI ; Elisabeth VARDAKA ; Konstantinos KOUNTOURAS ; Katerina PAPANIKOLOPOULOU ; Panagiotis KATSINELOS
Journal of Neurogastroenterology and Motility 2019;25(3):473-474
No abstract available.
Dyspepsia
;
Gastroesophageal Reflux
;
Helicobacter pylori
;
Helicobacter
;
Trimebutine
3.The Effect of Trimebutine on the Overlap Syndrome Model of Guinea Pigs
Zahid HUSSAIN ; Da Hyun JUNG ; Young Ju LEE ; Hyojin PARK
Journal of Neurogastroenterology and Motility 2018;24(4):669-675
BACKGROUND/AIMS: Functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common gastrointestinal (GI) disorders and these patients frequently overlap. Trimebutine has been known to be effective in controlling FD co-existing diarrhea-dominant IBS, however its effect on overlap syndrome (OS) patients has not been reported. Therefore, we investigated the effect of trimebutine on the model of OS in guinea pigs. METHODS: Male guinea pigs were used to evaluate the effects of trimebutine in corticotropin-releasing factor (CRF) induced OS model. Different doses (3, 10, and 30 mg/kg) of trimebutine were administered orally and incubated for 1 hour. The next treatment of 10 μg/kg of CRF was intraperitoneally injected and stabilized for 30 minutes. Subsequently, intragastric 3 mL charcoal mix was administered, incubated for 10 minutes and the upper GI transit analyzed. Colonic transits were assessed after the same order and concentrations of trimebutine and CRF treatment by fecal pellet output assay. RESULTS: Different concentrations (1, 3, and 10 μg/kg) of rat/human CRF peptides was tested to establish the OS model in guinea pigs. CRF 10 μg/kg was the most effective dose in the experimental OS model of guinea pigs. Trimebutine (3, 10, and 30 mg/kg) treatment significantly reversed the upper and lower GI transit of CRF induced OS model. Trimebutine significantly increased upper GI transit while it reduced fecal pellet output in the CRF induced OS model. CONCLUSIONS: Trimebutine has been demonstrated to be effective on both upper and lower GI motor function in peripheral CRF induced OS model. Therefore, trimebutine might be an effective drug for the treatment of OS between FD and IBS patients.
Animals
;
Charcoal
;
Colon
;
Corticotropin-Releasing Hormone
;
Dyspepsia
;
Guinea Pigs
;
Guinea
;
Humans
;
Irritable Bowel Syndrome
;
Male
;
Peptides
;
Trimebutine
4.Effect of antispasmodic agents for the treatment of irritable bowel syndrome
Journal of the Korean Medical Association 2018;61(7):428-434
Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS.
Abdominal Pain
;
Citric Acid
;
Colon
;
Gastrointestinal Motility
;
Humans
;
Hypersensitivity
;
Irritable Bowel Syndrome
;
Muscle Spasticity
;
Parasympatholytics
;
Peristalsis
;
Phloroglucinol
;
Simethicone
;
Spasm
;
Trimebutine
5.The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment.
Gulcan S KARABULUT ; Omer F BESER ; Ethem ERGINOZ ; Tufan KUTLU ; Fugen C COKUGRAS ; Tulay ERKAN
Journal of Neurogastroenterology and Motility 2013;19(1):90-93
BACKGROUND/AIMS: Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders and when compared to the vast knowledge pertaining to adults with IBS, very little is known about IBS in children and adolescents. We aimed to explore the prevalence of IBS, identify symptoms and contributing factors and also to examine the efficacy of trimebutine maleate in children and adolescents. METHODS: The study involved 345 children and adolescents (4-18 years) and parents were requested to fill in a questionnaire, Rome III criteria was used to diagnose IBS. To exclude organic disease, all patients underwent medical investigations. Half of the randomly selected IBS patients were treated with trimebutine maleate while the rest of IBS patients were not. The IBS patients were reevaluated at the end of 3 weeks. RESULTS: The prevalence of IBS according to Rome III criteria in children and adolescents was 22.6% and IBS with constipation was the predominant subtype. Back pain (OR, 6.68), headache (OR, 4.72) and chronic fatigue (OR, 3.74) were significantly higher in IBS group. The prevalence of IBS in both parents and depression in mothers was greater for the patient group than the healthy controls (P < 0.0001). The prevalence of functional dyspepsia in IBS group was 80.8% and was significantly higher than control group. Clinical recovery was seen in 94.9% of the trimebutine maleate group versus spontaneous recovery in 20.5% of the non-medicated group. The difference was significant (P < 0.0001). CONCLUSIONS: IBS is a common disorder in children and adolescents. IBS is closely associated with somatic and familial factors. Trimebutine maleate is effective for pediatric IBS patients.
Adolescent
;
Adult
;
Back Pain
;
Child
;
Constipation
;
Depression
;
Dyspepsia
;
Fatigue
;
Gastrointestinal Diseases
;
Headache
;
Humans
;
Incidence
;
Irritable Bowel Syndrome
;
Maleates
;
Mothers
;
Parents
;
Prevalence
;
Surveys and Questionnaires
;
Rome
;
Trimebutine
6.Comparative study on irritable bowel syndrome treated with acupuncture and western medicine.
Zhi-Min SHI ; Ye-Shan ZHU ; Qing-Xian WANG ; Miao-Na LEI
Chinese Acupuncture & Moxibustion 2011;31(7):607-609
OBJECTIVETo compare the differences in the therapeutic effect on irritable bowel syndrome (IBS) between acupuncture at Tianshu (ST 25) and Dachangshu (BL 25) and western medication with Trimebutine Maleate.
METHODSForty cases were divided randomly into an acupuncture group and a western medication group, 20 cases in each one. In acupuncture group, acupuncture was applied to Tianshu (ST 25) and Dachangshu (BL 25). Ziwu Daojiu needling technique was adopted, once daily. In western medication group, Trimebutine Maleate capsule was administered, 2 capsules in each time, 3 times per day. The assessment on the therapeutic effect was performed in 4 weeks of treatment in two groups.
RESULTSAs compared with those before treatment, the time of abdominal pain, the frequency of abdominal pain, the morbidity of abnormal stool appearance, the morbidity of defecation abnormality, the morbidity of mucus stool and the score of bloating or abdominal pain on bowel movement were all reduced after treatment in two groups (all P < 0.01). The results in acupuncture group were much more significant than those in western medication group (the total score: 16.70 +/- 2.40 vs 15.70 +/- 3.01, P < 0.01). The total effective rate in acupuncture group was 95.0% (19/20), which was superior to that of 70.0% (14/20) in western medication group (P < 0.05).
CONCLUSIONAcupuncture at Tianshu (ST 25) and Dachangshu (BL 25) may remarkably relieve the clinical symptoms of IBS and its efficacy is superior to that of oral medication with Trimebutine Maleate.
Acupuncture Therapy ; Adolescent ; Adult ; Aged ; Child ; Female ; Humans ; Irritable Bowel Syndrome ; drug therapy ; therapy ; Male ; Middle Aged ; Trimebutine ; therapeutic use ; Young Adult
7.Pharmacokinetics and bioequivalence of trimebutine dispersive tablet in healthy subjects.
Hong JIANG ; Li DING ; Jin YANG ; Xin HUANG ; Guang-yu LIU ; Zheng-xing ZHANG
Acta Pharmaceutica Sinica 2004;39(3):208-211
AIMTo develop an HPLC-ESI-MS assay for determination of trimebutine in human plasma and to investigate the pharmacokinetics and bioequivalence of two trimebutine tablets in human.
METHODSAfter being made alkaline with saturated sodium bicarbonate, plasma was extracted by cyclohexane and separated by HPLC on a reversed-phase C18 column with a mobile phase of 10 mmol x L(-1) ammonium acetate buffer solution (pH 3.5)-methanol (18:82). HPLC-ESI-MS was performed in the selected ion monitoring (SIM) mode using target ions at m/z 388 for trimebutine and m/z 280 for the internal standard (sibutramine, IS). The fragmentor voltage was 50 V. A randomized cross-over design was performed in 20 healthy volunteers. In the two study periods, a single 100 mg dose of each tablet was administered to each volunteer.
RESULTSCalibration curve was linear over the range of 0.3 - 150 microg x L(-1). The main pharmacokinetic parameters of T1/2, Tmax and Cmax were (9.2 +/- 2.8) h, (1.0 +/- 0.3) h and (40 +/- 20) microg x L(-1) for the reference tablet; (9.2 +/- 2.3) h, (0.9 +/- 0.4) h and (41 +/- 20) microg x L(-1) for the test tablet. The relative bioavalability of the test tablet was (97 +/- 13)%. The results of variance analysis and two one-sided t-test showed that there was no significant difference between the two formulations in the AUC and Cmax.
CONCLUSIONThe assay was proved to be sensitive, accurate and convenient. The two formulations were bioequivalent.
Adult ; Area Under Curve ; Chromatography, High Pressure Liquid ; Gastrointestinal Agents ; administration & dosage ; pharmacokinetics ; Humans ; Male ; Spectrometry, Mass, Electrospray Ionization ; Tablets ; Therapeutic Equivalency ; Trimebutine ; administration & dosage ; pharmacokinetics
8.Efficacy of Fenoverine and Trimebutine in the Management of Irritable Bowel Syndrome: Multicenter Randomized Double-blind Non-inferiority Clinical Study.
Seong Hee KANG ; Yoon Tae JEEN ; Ja Seol KOO ; Yang Seo KOO ; Kyoung Oh KIM ; You Sun KIM ; Seung Yeong KIM ; Jeong Seop MOON ; Jong Jae PARK ; Il Hyun BAEK ; Sung Chul PARK ; Sung Joon LEE ; Jong Hun LEE ; Rok Seon CHOUNG ; Suck Chei CHOI
The Korean Journal of Gastroenterology 2013;62(5):278-287
BACKGROUND/AIMS: Antispasmodic agents have been used in the management of irritable bowel syndrome. However, systematic reviews have come to different conclusions about the efficacy in irritable bowel syndrome. Fenoverine acts as a synchronizer of smooth muscle in modulating the intracellular influx of calcium. We compared fenoverine with trimebutine for the treatment of patients with IBS. METHODS: A multicenter, randomized, double-blind, non-inferiority clinical study was conducted to compared fenoverine with trimebutine. Subjects were randomized to receive either fenoverine (100 mg three times a day) or trimebutine (150 mg three times a day) for 8 weeks. A total of 197 patients were analyzed by the intention-to-treat approach. The primary endpoint was the proportion of patients who had 30% reduction in abdominal pain or discomfort measured by bowel symptom scale (BSS) score at week 8 compared to the baseline. The secondary endpoints were changes of abdominal bloating, diarrhea, constipation, overall and total scores of BSS, and overall satisfaction. RESULTS: At week 8, fenoverine was shown to be non-inferior to trimebutine (treatment difference, 1.76%; 90% CI, -10.30-13.82; p=0.81); 69.23% (54 of 78 patients) of patients taking fenoverine and 67.47% (56 of 83 patients) of patients taking trimebutine showed 30% reduction in abdominal pain or discomfort compared to the baseline. There results of the secondary endpoints were also comparable between the fenoverine group and the trimebutine group. CONCLUSIONS: Fenoverine is non-inferior to trimebutine for treating IBS in terms of both efficacy and tolerability.
Abdominal Pain/etiology
;
Adult
;
Constipation/etiology
;
Diarrhea/etiology
;
Double-Blind Method
;
Drug Administration Schedule
;
Female
;
Humans
;
Irritable Bowel Syndrome/complications/*drug therapy
;
Male
;
Middle Aged
;
Parasympatholytics/*therapeutic use
;
Phenothiazines/*therapeutic use
;
Severity of Illness Index
;
Treatment Outcome
;
Trimebutine/*therapeutic use